CN101744792B - Fluticasone propionate and salmeterol xinafoate compound dry powder inhalation and preparation technology thereof - Google Patents
Fluticasone propionate and salmeterol xinafoate compound dry powder inhalation and preparation technology thereof Download PDFInfo
- Publication number
- CN101744792B CN101744792B CN 200810204741 CN200810204741A CN101744792B CN 101744792 B CN101744792 B CN 101744792B CN 200810204741 CN200810204741 CN 200810204741 CN 200810204741 A CN200810204741 A CN 200810204741A CN 101744792 B CN101744792 B CN 101744792B
- Authority
- CN
- China
- Prior art keywords
- lactose
- dry powder
- fluticasone propionate
- powder inhalation
- salmaterol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Technique | Ejecta (mg) |
Embodiment one | 7.3 |
Embodiment two | 6.7 |
Embodiment three | 6.9 |
Embodiment four | 6.9 |
Embodiment five | 7.1 |
Claims (5)
- FLUTICASONE PROPIONATE and salmaterol former times acid esters compound dry powder inhalation how, it is characterized in that this compound dry powder preparation is grouped into by the one-tenth of following weight percent proportioning:Active component: FLUTICASONE PROPIONATE 1.0%-9.0%; Salmaterol former times is acid esters 0.5%-1.0% how;Pharmaceutic adjuvant: lactose 90.5%-98.0%;Described lactose comprises lactose one and lactose two; Described lactose one is 10-90% at the Foradil Aerolizer formoterol fumarate proportion, and lactose two is 10-90% at the Foradil Aerolizer formoterol fumarate proportion; Described lactose one be the lactose granule size between 20-370 μ m, medium particle diameter 100-140 μ m; Described lactose two granular sizes between 10-260 μ m, its medium particle diameter 60-90 μ m.
- 2. the preparation technology of a FLUTICASONE PROPIONATE and salmeterol xinafoate compound dry powder inhalation is characterized in that this technique comprises the following steps:Prescription:Active component: FLUTICASONE PROPIONATE 1.0%-9.0%; Salmaterol former times is acid esters 0.5%-1.0% how;Pharmaceutic adjuvant: lactose 90.5%-98.0%;Described lactose comprises lactose one and lactose two; Described lactose one is 10-90% at the Foradil Aerolizer formoterol fumarate proportion, and lactose two is 10-90% at the Foradil Aerolizer formoterol fumarate proportion; Described lactose one be the lactose granule size between 20-370 μ m, medium particle diameter 100-140 μ m; Described lactose two granular sizes between 10-260 μ m, its medium particle diameter 60-90 μ m;Technique:(1) with active component FLUTICASONE PROPIONATE 1.0%-9.0%; Salmaterol former times, how acid esters 0.5%-1.0% mixed with the 90.5%-98.0% lactose, mixed the mixture that obtains principal agent and lactose after 0.5-1 hour;(2) with the mixture fill in multiple dose reservoir devices dry powder drug administration device, so that suck 13mm at every turn 3The dry powder content, dosage reaches 250 μ g/ salmaterol former times of every suction FLUTICASONE PROPIONATE acid esters 50 μ g how.
- 3. the preparation technology of described FLUTICASONE PROPIONATE and salmeterol xinafoate compound dry powder inhalation according to claim 2 is characterized in that, when step (1) is mixed, in the cavity of high speed shear mixer, horizontal direction and vertical direction blade is set.
- 4. the preparation technology of described FLUTICASONE PROPIONATE and salmeterol xinafoate compound dry powder inhalation according to claim 3, it is characterized in that, when step (1) was mixed, the rotating speed of described horizontal direction blade was 50-500rpm, and the rotating speed of vertical direction blade is 30-1000rpm.
- 5. the preparation technology of described FLUTICASONE PROPIONATE and salmeterol xinafoate compound dry powder inhalation according to claim 4, it is characterized in that, when step (1) was mixed, the rotating speed of described horizontal direction blade was 300rpm, and the rotating speed of vertical direction blade is 300rpm.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200810204741 CN101744792B (en) | 2008-12-17 | 2008-12-17 | Fluticasone propionate and salmeterol xinafoate compound dry powder inhalation and preparation technology thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200810204741 CN101744792B (en) | 2008-12-17 | 2008-12-17 | Fluticasone propionate and salmeterol xinafoate compound dry powder inhalation and preparation technology thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101744792A CN101744792A (en) | 2010-06-23 |
CN101744792B true CN101744792B (en) | 2013-04-17 |
Family
ID=42472808
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200810204741 Active CN101744792B (en) | 2008-12-17 | 2008-12-17 | Fluticasone propionate and salmeterol xinafoate compound dry powder inhalation and preparation technology thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101744792B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107095875B (en) * | 2016-02-23 | 2022-03-18 | 天津金耀集团有限公司 | Salmeterol xinafoate and fluticasone propionate compound powder inhalant composition |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0416951B1 (en) * | 1989-09-08 | 1994-01-12 | Glaxo Group Limited | Medicaments comprising salmeterol and fluticason |
US6503537B2 (en) * | 1997-03-20 | 2003-01-07 | Schering Corporation | Preparation of powder agglomerates |
US20070053843A1 (en) * | 2003-10-28 | 2007-03-08 | Dawson Michelle L | Inhalable pharmaceutical formulations employing lactose anhydrate and methods of administering the same |
-
2008
- 2008-12-17 CN CN 200810204741 patent/CN101744792B/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0416951B1 (en) * | 1989-09-08 | 1994-01-12 | Glaxo Group Limited | Medicaments comprising salmeterol and fluticason |
US6503537B2 (en) * | 1997-03-20 | 2003-01-07 | Schering Corporation | Preparation of powder agglomerates |
US20070053843A1 (en) * | 2003-10-28 | 2007-03-08 | Dawson Michelle L | Inhalable pharmaceutical formulations employing lactose anhydrate and methods of administering the same |
Non-Patent Citations (1)
Title |
---|
孙丽霞.哮喘治疗药Seretide.《国外医药-合成药、生化药、制剂分册》.1999,第20卷(第4期),222. * |
Also Published As
Publication number | Publication date |
---|---|
CN101744792A (en) | 2010-06-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104080444B (en) | The dry composition agent comprising corticosteroid and BETA adrenergics for inhalation | |
KR102337781B1 (en) | Ultra low density pulmonary powders | |
KR20090023650A (en) | Compositions of glycopyrronium salt for inhalation | |
MXPA02010218A (en) | Pharmaceutical formulations for dry powder inhalers in the form of hard-pellets. | |
CN102325523A (en) | Pharmaceutical composition for inhalation | |
CN1635870A (en) | Medicinal aerosol formulations | |
CN109745565B (en) | Dry powder composition for inhalation and preparation method thereof | |
CN108289962A (en) | The method for preparing the dry powder formulations comprising anticholinergic drug, corticosteroid and beta-adrenergic medicine | |
CN111202722A (en) | Lopinavir inhalation dry powder pharmaceutical composition and preparation method thereof | |
JP2015519394A (en) | Dry powder for inhalation preparation containing salmeterol xinafoate, fluticasone propionate and tiotropium bromide, and method for producing the same | |
CN109464429B (en) | Inhalation pressure quantitative aerosol pharmaceutical composition and preparation method thereof | |
CN107496388B (en) | Powdery preparation containing formoterol and tiotropium salt composition and preparation method thereof | |
CN111358773B (en) | Peramivir dry powder inhalant and preparation method thereof | |
CN101744792B (en) | Fluticasone propionate and salmeterol xinafoate compound dry powder inhalation and preparation technology thereof | |
KR101728116B1 (en) | Dry powder composition for inhalation comprising tiotropium or pharmaceutically acceptable salt thereof | |
CN104398497B (en) | Itraconazole inhalation powder spray and preparation method thereof | |
CN109745564A (en) | A kind of preparation method sucking dry powder composite | |
RU2338552C2 (en) | Pharmaceutical composition for inhalation | |
US11304937B2 (en) | Medicinal composition for inhalation | |
CN101756943A (en) | Mometasone furoate dry powder inhalation and preparing process thereof | |
CN108721219A (en) | A kind of bioadhesive lung inhales Nano Composite Particles and preparation method thereof | |
CN105250244A (en) | Pulmonary inhalation curcumin-phospholipid complex chitosan microspheres and preparation method thereof | |
CN105078932A (en) | Method for increasing fine particle proportion of medicinal preparation and preparation | |
CN112137957B (en) | Medicinal inhalation aerosol and preparation method thereof | |
CN111297837B (en) | Preparation method of dry powder inhalant |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: ZHANG KAI Free format text: FORMER OWNER: SHANGHAI FOSUN PUSHI PHARMACEUTICAL TECHNOLOGY CO., LTD. Effective date: 20120615 Free format text: FORMER OWNER: SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD. Effective date: 20120615 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20120615 Address after: Pudong Zhangjiang road 201203 Bing Shanghai No. 306 Building No. 3 2 floor Applicant after: Zhang Kai Address before: 201203 Shanghai City Bing Road No. 306 2 floor Applicant before: Shanghai Fosun Pushi Pharmaceutical Technology Co., Ltd. Co-applicant before: Shanghai Fosun Pharmaceutical (Group) Limited by Share Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: SUZHOU OUMINI PHARMACEUTICALS CO., LTD. Free format text: FORMER OWNER: ZHANG KAI Effective date: 20150615 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20150615 Address after: 215421 Taicang city in Jiangsu Province town of Shaxi Biomedical Park Road No. 5, Zhenhui plant No. 6 Patentee after: Suzhou Pharmaceutical Co., Ltd. Address before: Pudong Zhangjiang road 201203 Bing Shanghai No. 306 Building No. 3 2 floor Patentee before: Zhang Kai |
|
CP02 | Change in the address of a patent holder |
Address after: No. 69, Zhen Xi Road, bio Pharmaceutical Industrial Park, Shaxi Town, Taicang, Jiangsu Patentee after: Suzhou Pharmaceutical Co., Ltd. Address before: 215421 Taicang city in Jiangsu Province town of Shaxi Biomedical Park Road No. 5, Zhenhui plant No. 6 Patentee before: Suzhou Pharmaceutical Co., Ltd. |
|
CP02 | Change in the address of a patent holder |